| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Response to Sung, Rosenberg, and Yang
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Yeo W.; Ueno T.; Li H.; Huang S.-M.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4)
|
Kuo C.-T.; Chen C.-L.; Li C.-C.; Huang G.-S.; Ma W.-Y.; Hsu W.-F.; Lin C.-H.; YEN-SHEN LU; Wo A.M. |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial
|
Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.;Chang S.-H.;Kuo W.-H.;Kuo C.-H.;Li S.-Y.;Wang M.-Y.;Chang D.-Y.;Yen-Shen Lu;Huang C.-S.;Cheng A.-L.;Lin C.-H.;Chen P.-C.; Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; YEN-SHEN LU; Huang C.-S.; Cheng A.-L.; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2�Vnegative advanced breast cancer: final overall survival results from SOLAR-1
|
Andr? F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU; Inoue K.; P?pai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. |
| 臺大學術典藏 |
2021-03-03T10:26:44Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
Yen-Shen Lu; Lee, Keun Seok; Chao, Tsu Yi; Tseng, Ling Ming; Chitapanarux, Imjai; Chen, Shin Cheh; Liu, Chien Ting; Sohn, Joohyuk; Kim, Jee Hyun; Chang, Yuan Ching; Yang, Youngsen; Shotelersuk, Kanjana; Jung, Kyung Hae; Valenti, Roberta; Slader, Cassandra; Gao, Melissa; Park, Yeon Hee |
| 臺大學術典藏 |
2021-03-03T10:26:43Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HRþ advanced breast cancer
|
Tolaney, Sara M.; Im, Young Hyuck; Calvo, Emiliano; Yen-Shen Lu; Hamilton, Erika; Forero-Torres, Andres; Bachelot, Thomas; Maur, Michela; Fasolo, Angelica; Tiedt, Ralph; Nardi, Lisa; Stammberger, Uz; Abdelhady, Ahmed M.; Ruan, Shiling; Lee, Soo Chin |
